Clinical Rheumatology

, Volume 32, Issue 12, pp 1827–1832 | Cite as

Tumor necrosis factor alpha inhibitors in patients with Takayasu's arteritis refractory to standard immunosuppressive treatment: cases series and review of the literature

Case Based Review

Abstract

The objective of this study was to report the long-term use of tumor necrosis factor (TNF) inhibitors in case series of patients with Takayasu's arteritis refractory to standard immunosuppressive treatment. Nine women (median age of 29 years) with refractory Takayasu's arteritis were treated with TNF inhibitors. Prior to TNF inhibitor administration, all patients received standard immunosuppressive treatment for 16 to 112 months including steroids and immunomodulators. All but one patient presented with high activity of disease (median ESR 80 mm/h, C-reactive protein level 16.8 mg/l, interleukin-6 level 7.2 pg/ml) that was confirmed with positron emission tomography (PET) with 18F-deoxyglucose. Eight patients were treated with infliximab and one was treated with adalimumab, respectively. The median duration of treatment was 36 months (12 to 84 months). For induction treatment, we used infliximab 200–300 mg every 4–6 weeks and adalimumab 40 mg every 2 weeks. The treatment resulted in complete remission in five (55.6 %) patients and incomplete remission in three (33.3 %) patients. We were able to taper the dose of prednisone to ≤10 mg daily in all patients. Median levels of ESR, C-reactive protein, and interleukin-6 diminished to 20 mm/h, 1.0 mg/l, and 1.0 pg/ml, respectively. Repeated PET showed lower activity of vasculitis in six (85.7 %) of seven patients. The treatment was safe and well-tolerated. Only one patient developed allergic reactions after infusions of infliximab. Four patients developed relapse of vasculitis when we tried to increase the dosing interval of infliximab to 6–8 weeks. TNF inhibitors were highly effective and safe in patients with refractory Takayasu's arteritis.

Keywords

Infliximab Takayasu's arteritis TNF inhibitors 

Notes

Disclosures

None.

References

  1. 1.
    Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, Flores-Suarez LF, Gross WL, Guillevin L, Hagen EC, Hoffman GS, Jayne DR, Kallenberg CG, Lamprecht P, Langford CA, Luqmani RA, Mahr AD, Matteson EL, Merkel PA, Ozen S, Pusey CD, Rasmussen N, Rees AJ, Scott DG, Specks U, Stone JH, Takahashi K, Watts RA (2013) 2012 revised international Chapel Hill consensus conference nomenclature of vasculitides. Arthritis Rheum 65:1–11PubMedCrossRefGoogle Scholar
  2. 2.
    Mason JC (2010) Takayasu arteritis—advances in diagnosis and management. Nat Rev Rheumatol 6:406–415PubMedCrossRefGoogle Scholar
  3. 3.
    Comarmond C, Plaisier E, Dahan K, Mirault T, Emmerich J, Amoura Z, Cacoub P, Saadoun D (2012) Anti TNF-α in refractory Takayasu's arteritis: cases series and review of the literature. Autoimmun Rev 11:678–684PubMedCrossRefGoogle Scholar
  4. 4.
    Mevorach D, Leibowitz G, Brezis M, Raz E (1992) Induction of remission in a patient with Takayasu's arteritis by low dose pulses of methotrexate. Ann Rheum Dis 51:904–905PubMedCrossRefGoogle Scholar
  5. 5.
    Valsakumar AK, Valappil UC, Jorapur V, Garg N, Nityanand S, Sinha N (2003) Role of immunosuppressive therapy on clinical, immunological, and angiographic outcome in active Takayasu's arteritis. J Rheumatol 30:1793–1798PubMedGoogle Scholar
  6. 6.
    Shelhamer JH, Volkman DJ, Parrillo JE, Lawley TJ, Johnston MR, Fauci AS (1985) Takayasu's arteritis and its therapy. Ann Intern Med 103:121–126PubMedCrossRefGoogle Scholar
  7. 7.
    Hoffman GS, Leavitt RY, Kerr GS, Rottem M, Sneller MC, Fauci AS (1994) Treatment of glucocorticoid-resistant or relapsing Takayasu arteritis with methotrexate. Arthritis Rheum 37:578–582PubMedCrossRefGoogle Scholar
  8. 8.
    de Souza AW, da Silva MD, Machado LS, Oliveira AC, Pinheiro FA, Sato EI (2012) Short-term effect of leflunomide in patients with Takayasu arteritis: an observational study. Scand J Rheumatol 41:227–230PubMedCrossRefGoogle Scholar
  9. 9.
    Kötter I, Henes JC, Wagner AD, Loock J, Gross WL (2012) Does glucocorticosteroid-resistant large-vessel vasculitis (giant cell arteritis and Takayasu arteritis) exist and how can remission be achieved? A critical review of the literature. Clin Exp Rheumatol 30:S114–S129PubMedGoogle Scholar
  10. 10.
    Schäfer VS, Zwerina J (2012) Biologic treatment of large-vessel vasculitides. Curr Opin Rheumatol 24:31–37PubMedCrossRefGoogle Scholar
  11. 11.
    Maksimowicz-McKinnon K, Hoffman GS (2007) Takayasu arteritis: what is the long-term prognosis? Rheum Dis Clin North Am 33:777–786PubMedCrossRefGoogle Scholar
  12. 12.
    Wallis RS, Ehlers S (2005) Tumor necrosis factor and granuloma biology: explaining the differential infection risk of etanercept and infliximab. Semin Arthritis Rheum 34:34–38PubMedCrossRefGoogle Scholar
  13. 13.
    Park MC, Lee SW, Park YB, Lee SK (2006) Serum cytokine profiles and their correlations with disease activity in Takayasu's arteritis. Rheumatology (Oxford) 45:545–548PubMedCrossRefGoogle Scholar
  14. 14.
    Tripathy NK, Gupta PC, Nityanand S (2006) High TNF-alpha and low IL-2 producing T cells characterize active disease in Takayasu's arteritis. Clin Immunol 118:154–158PubMedCrossRefGoogle Scholar
  15. 15.
    Schmidt J, Kermani TA, Bacani AK, Crowson CS, Matteson EL, Warrington KJ (2012) Tumor necrosis factor inhibitors in patients with Takayasu arteritis: experience from a referral center with long-term followup. Arthritis Care Res (Hoboken) 64:1079–1083PubMedGoogle Scholar
  16. 16.
    Mekinian A, Néel A, Sibilia J, Cohen P, Connault J, Lambert M, Federici L, Berthier S, Fiessinger JN, Godeau B, Marie I, Guillevin L, Hamidou M, Fain O, Club Rhumatismes et Inflammation, French Vasculitis Study Group and Société Nationale Française de Médecine Interne (2012) Efficacy and tolerance of infliximab in refractory Takayasu arteritis: French multicentre study. Rheumatology (Oxford) 51:882–886PubMedCrossRefGoogle Scholar
  17. 17.
    Quartuccio L, Schiavon F, Zuliani F, Carraro V, Catarsi E, Tavoni AG, Bombardieri S, Punzi L, De Vita S (2012) Long-term efficacy and improvement of health-related quality of life in patients with Takayasu's arteritis treated with infliximab. Clin Exp Rheumatol 30:922–928PubMedGoogle Scholar
  18. 18.
    Molloy ES, Langford CA, Clark TM, Gota CE, Hoffman GS (2008) Anti-tumour necrosis factor therapy in patients with refractory Takayasu arteritis: long-term follow-up. Ann Rheum Dis 67:1567–1569PubMedCrossRefGoogle Scholar
  19. 19.
    Arend WP, Michel BA, Bloch DA, Hunder GG, Calabrese LH, Edworthy SM, Fauci AS, Leavitt RY, Lie JT, Lightfoot RW Jr et al (1990) The American College of Rheumatology 1990 criteria for the classification of Takayasu arteritis. Arthritis Rheum 33:1129–1134PubMedCrossRefGoogle Scholar
  20. 20.
    Kerr GS, Hallahan CW, Giordano J, Leavitt RY, Fauci AS, Rottem M, Hoffman GS (1994) Takayasu arteritis. Ann Intern Med 120:919–929PubMedCrossRefGoogle Scholar
  21. 21.
    Blockmans D (2011) PET in vasculitis. Ann N Y Acad Sci 1228:64–70PubMedCrossRefGoogle Scholar
  22. 22.
    Lee KH, Cho A, Choi YJ, Lee SW, Ha YJ, Jung SJ, Park MC, Lee JD, Lee SK, Park YB (2012) The role of (18) F-fluorodeoxyglucose-positron emission tomography in the assessment of disease activity in patients with Takayasu arteritis. Arthritis Rheum 64:866–875PubMedCrossRefGoogle Scholar
  23. 23.
    Misra R, Danda D, Rajappa SM, Ghosh A, Gupta R, Mahendranath KM, Jeyaseelan L, Lawrence A, Bacon PA, on behalf of the Indian Rheumatology Vasculitis (IRAVAS) group (2013) Development and initial validation of the Indian Takayasu Clinical Activity Score (ITAS2010). Rheumatology (Oxford). doi:10.1093/rheumatology/ket128 PubMedGoogle Scholar
  24. 24.
    Hata A, Noda M, Moriwaki R, Numano F (1996) Angiographic findings of Takayasu arteritis: new classification. Int J Cardiol 54:S155–S163PubMedCrossRefGoogle Scholar
  25. 25.
    Wen D, Du X, Ma CS (2012) Takayasu arteritis: diagnosis, treatment and prognosis. Int Rev Immunol 31:462–473PubMedCrossRefGoogle Scholar
  26. 26.
    Direskeneli H, Aydin SZ, Merkel PA (2011) Assessment of disease activity and progression in Takayasu's arteritis. Clin Exp Rheumatol 29:S86–S91PubMedGoogle Scholar
  27. 27.
    Pipitone N, Olivieri I, Salvarani C, Italian Society of Rheumatology (2012) Recommendations of the Italian Society of Rheumatology for the treatment of the primary large-vessel vasculitis with biological agents. Clin Exp Rheumatol 30:S139–S161PubMedGoogle Scholar
  28. 28.
    Nunes G, Neves FS, Melo FM, de Castro GR, Zimmermann AF, Pereira IA (2010) Takayasu arteritis: anti-TNF therapy in a Brazilian setting. Rev Bras Reumatol 50:291–298PubMedCrossRefGoogle Scholar
  29. 29.
    Hoffman GS, Merkel PA, Brasington RD, Lenschow DJ, Liang P (2004) Anti-tumor necrosis factor therapy in patients with difficult to treat Takayasu arteritis. Arthritis Rheum 50:2296–2304PubMedCrossRefGoogle Scholar
  30. 30.
    Langford CA (2008) Drug insight: anti-tumor necrosis factor therapies for the vasculitic diseases. Nat Clin Pract Rheumatol 4:364–370PubMedGoogle Scholar
  31. 31.
    Hoyer BF, Mumtaz IM, Loddenkemper K, Bruns A, Sengler C, Hermann KG, Maza S, Keitzer R, Burmester GR, Buttgereit F, Radbruch A, Hiepe F (2012) Takayasu arteritis is characterised by disturbances of B cell homeostasis and responds to B cell depletion therapy with rituximab. Ann Rheum Dis 71:75–79PubMedCrossRefGoogle Scholar
  32. 32.
    Arnaud L, Haroche J, Mathian A, Gorochov G, Amoura Z (2011) Pathogenesis of Takayasu's arteritis: a 2011 update. Autoimmun Rev 11:61–67PubMedCrossRefGoogle Scholar
  33. 33.
    Unizony S, Stone JH, Stone JR (2013) New treatment strategies in large-vessel vasculitis. Curr Opin Rheumatol 25:3–9PubMedCrossRefGoogle Scholar
  34. 34.
    Nishimoto N, Nakahara H, Yoshio-Hoshino N, Mima T (2008) Successful treatment of a patient with Takayasu arteritis using a humanized anti-interleukin-6 receptor antibody. Arthritis Rheum 58:1197–1200PubMedCrossRefGoogle Scholar
  35. 35.
    Unizony S, Arias-Urdaneta L, Miloslavsky E, Arvikar S, Khosroshahi A, Keroack B, Stone JR, Stone JH (2012) Tocilizumab for the treatment of large-vessel vasculitis (giant cell arteritis, Takayasu arteritis) and polymyalgia rheumatica. Arthritis Care Res (Hoboken) 64:1720–1729PubMedCrossRefGoogle Scholar
  36. 36.
    Salvarani C, Magnani L, Catanoso MG, Pipitone N, Versari A, Dardani L, Pulsatelli L, Meliconi R, Boiardi L (2012) Rescue treatment with tocilizumab for Takayasu arteritis resistant to TNF-α blockers. Clin Exp Rheumatol 30:S90–S93PubMedGoogle Scholar
  37. 37.
    Seitz M, Reichenbach S, Bonel HM, Adler S, Wermelinger F, Villiger PM (2011) Rapid induction of remission in large vessel vasculitis by IL-6 blockade. A case series. Swiss Med Wkly 141:w13156PubMedGoogle Scholar

Copyright information

© Clinical Rheumatology 2013

Authors and Affiliations

  • P. I. Novikov
    • 1
  • I. O. Smitienko
    • 2
  • S. V. Moiseev
    • 1
    • 3
  1. 1.Clinic of Nephrology, Internal and Occupational Diseases, University Clinical Hospital #3First Moscow State Medical UniversityMoscowRussia
  2. 2.Russian University of Peoples’ FriendshipMoscowRussia
  3. 3.MoscowRussia

Personalised recommendations